These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38037386)

  • 1. Influenza B virus neuraminidase: a potential target for next-generation vaccines?
    Do THT; Wheatley AK; Kent SJ; Koutsakos M
    Expert Rev Vaccines; 2024; 23(1):39-48. PubMed ID: 38037386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
    Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
    mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
    Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
    J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
    Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
    mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model.
    Rosu ME; Kok A; Bestebroer TM; de Meulder D; Verveer EP; Pronk MR; Dekker LJM; Luider TM; Richard M; van den Brand JMA; Fouchier RAM; Herfst S
    J Virol; 2022 Mar; 96(6):e0195921. PubMed ID: 35107371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody.
    Khalil AM; Piepenbrink MS; Markham I; Basu M; Martinez-Sobrido L; Kobie JJ
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting neuraminidase: the next frontier for broadly protective influenza vaccines.
    Wu NC; Ellebedy AH
    Trends Immunol; 2024 Jan; 45(1):11-19. PubMed ID: 38103991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
    Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
    J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase.
    Do THT; Wille M; Wheatley AK; Koutsakos M
    J Virol; 2024 Oct; 98(10):e0118624. PubMed ID: 39360825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly Protective Neuraminidase-Based Influenza Vaccines and Monoclonal Antibodies: Target Epitopes and Mechanisms of Action.
    Abbadi N; Mousa JJ
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface.
    Wolters RM; Ferguson JA; Nuñez IA; Chen EE; Sornberger T; Myers L; Oeverdieck S; Raghavan SSR; Kona C; Handal LS; Esilu TE; Davidson E; Doranz BJ; Engdahl TB; Kose N; Williamson LE; Creech CB; Gibson-Corley KN; Ward AB; Crowe JE
    Immunity; 2024 Jun; 57(6):1413-1427.e9. PubMed ID: 38823390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B.
    Portela Catani JP; Ysenbaert T; Smet A; Vuylsteke M; Vogel TU; Saelens X
    PLoS One; 2023; 18(1):e0280825. PubMed ID: 36689429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-neuraminidase immunity in the combat against influenza.
    Zhang X; Ross TM
    Expert Rev Vaccines; 2024; 23(1):474-484. PubMed ID: 38632930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
    Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
    Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.
    Eichelberger MC; Monto AS
    J Infect Dis; 2019 Apr; 219(Suppl_1):S75-S80. PubMed ID: 30715357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.
    Madsen A; Dai YN; McMahon M; Schmitz AJ; Turner JS; Tan J; Lei T; Alsoussi WB; Strohmeier S; Amor M; Mohammed BM; Mudd PA; Simon V; Cox RJ; Fremont DH; Krammer F; Ellebedy AH
    Immunity; 2020 Oct; 53(4):852-863.e7. PubMed ID: 32976769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza vaccine: progress in a vaccine that elicits a broad immune response.
    Isakova-Sivak I; Stepanova E; Mezhenskaya D; Matyushenko V; Prokopenko P; Sychev I; Wong PF; Rudenko L
    Expert Rev Vaccines; 2021 Sep; 20(9):1097-1112. PubMed ID: 34348561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.